产品说明书
α-Lipoic Acid
 |
同义名 : | DL-硫辛酸 ;Thioctic acid;DL-α-Lipoic acid;(±)-α-Lipoic acid |
| CAS号 : | 1077-28-7 | |
| 货号 : | A196877 | |
| 分子式 : | C8H14O2S2 | |
| 纯度 : | 97% | |
| 分子量 : | 206.33 | |
| MDL号 : | MFCD00005474 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(508.9 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | α-Lipoic Acid, a naturally occurring substance, has many biological activities[1]. In vitro studies, α-lipoic acid could increase the level of PON1 and PON3 protein, as well as regulate their mRNA expression in HepG2 cells[2]. Besides this, it was found that α-lipoic acid had good antioxidant activity in C2C12 myotubes, through upregulating catalase expression[3]. In vivo studies, α-lipoic acid has the ability of protecting the cortical neurons against the high-fat diet-induced cerebral damage in mice, by inhibiting the oxidative stress and inflammatory reactions[4]. In addition, α-lipoic acid could contribute to the mitigation of α-cypermethrin-induced toxicity in cerebellum of treated rats[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01931787 | Recurrent Small Cell Lung Canc... 展开 >>er 收起 << | Phase 1 | Completed | - | United States, North Carolina ... 展开 >> Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States, 27157 收起 << |
| NCT01471652 | Chronic Fatigue Syndrome | Phase 2 | Withdrawn(PI left the institut... 展开 >>ion) 收起 << | - | United States, New York ... 展开 >> Columbia University Department of Clinical Genetics New York, New York, United States, 10032 收起 << |
| NCT00664001 | Acute Mountain Sickness | Phase 3 | Completed | - | United Kingdom ... 展开 >> University of Edinburgh Edinburgh, United Kingdom 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.85mL 0.97mL 0.48mL |
24.23mL 4.85mL 2.42mL |
48.47mL 9.69mL 4.85mL |
| 参考文献 |
|---|